PreviewDealogy is opening soon. The businesses shown are examples illustrating how the marketplace works, not live opportunities.Join the waitlist
← All businessesLogistics, Transport & Distribution / Medical & Pharma Supplies / Pharmaceutical wholesale

Pharmaceutical Wholesaler With A Freehold Warehouse In London

London, Greater London, LondonIdentity protected

Available

Pharmaceutical wholesaler with a freehold warehouse in London

About this business

A pharmaceutical wholesaler supplying prescription and over-the-counter medicines to independent pharmacies and dispensing practices across London. Its warehouse is owned freehold, so a buyer acquires the building as well as the trade. The team of 7 handles ordering, picking, temperature-controlled storage and delivery. Sales have held close to £4.25m in each year since 2022, while EBITDA has climbed every year to £518k, which points to better buying and tighter running costs rather than extra volume. A new owner takes on a compact operation with steady demand and room to add new pharmacy accounts.

Key investment highlights

  • Freehold warehouse on a London industrial estate
  • EBITDA up every year since 2022, now £518k
  • Turnover steady at around £4.25m
  • Small team of 7 covering stock and delivery

Reason for sale

The founders are selling to concentrate on a separate healthcare venture they run.

Nothing flagged on the two questions buyers ask first

No flag

Revenue going backwards and one client being too much of it are the two things that end most deals in due diligence. Both are shown here up front, from the figures the seller supplied.

  • Revenue directionNo flag

    Turnover is flat year on year.

    • 2022: baseline
    • 2023 (+0.1%)
    • 2024 (-0.0%)
    • 2025 (+0.6%)
    • 2026 (-0.0%)
    • Peak 2025 to latest 2026: -0.0%

    5 years of turnover, 2022 to 2026, as supplied by the seller.

  • Client concentrationNot stated

    The seller has not declared what share of revenue the largest clients represent.

    No declaration supplied. Client concentration cannot be derived from accounts.

EBITDA margin widened from 9.6% in 2022 to 12.2% in 2026.

These are observations from the supplied figures, not a view on whether this business is worth buying. Nothing here predicts an outcome.

Computing valuation...

What happens next

Submit an enquiry to the seller. Once they approve it, you sign a non-disclosure agreement and gain access to the information memorandum, the financials and a secure deal room with the seller.